Indian court rejects patent linkage in Bayer'ssorafenib case
This article was originally published in Scrip
Executive Summary
The High Court in Delhi, India has indicted Bayer for "speculative" litigation in a case concerning Cipla's marketing application for a generic version of the anticancer sorafenib tosylate.